DCTH Delcath Systems Inc
Price (delayed)
$12.14
Market cap
$405.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$374.14M
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is
Highlights
Delcath Systems's debt has shrunk by 90% YoY and by 66% QoQ
Delcath Systems's gross profit has soared by 68% from the previous quarter
Key stats
What are the main financial stats of DCTH
Market
Valuations
Earnings
Shares outstanding
33.4M
Market cap
$405.51M
Enterprise value
$374.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.65
Price to sales (P/S)
9.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.06
Revenue
$37.21M
Gross profit
$31.02M
Operating income
-$12.44M
Net income
-$26.39M
EBIT
-$26.51M
EBITDA
-$26.28M
Free cash flow
-$19.24M
Per share
Balance sheet
Liquidity
EPS
-$0.93
EPS diluted
-$0.93
Free cash flow per share
-$0.67
Book value per share
$2.15
Revenue per share
$1.3
TBVPS
$2.69
Total assets
$76.59M
Total liabilities
$7.84M
Debt
$1.04M
Equity
$68.75M
Working capital
$67.62M
Debt to equity
0.02
Current ratio
12.01
Quick ratio
10.44
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
-70.6%
Gross margin
83.4%
Net margin
-70.9%
Operating margin
-33.4%
Return on assets
-59.2%
Return on equity
-109.8%
Return on invested capital
-140%
Return on capital employed
-37.6%
Return on sales
-71.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DCTH stock price
How has the Delcath Systems stock price performed over time
Intraday
2.27%
1 week
5.11%
1 month
-11.52%
1 year
116.79%
YTD
0.83%
QTD
-4.63%
Financial performance
How have Delcath Systems's revenue and profit performed over time
Revenue
$37.21M
Gross profit
$31.02M
Operating income
-$12.44M
Net income
-$26.39M
Gross margin
83.4%
Net margin
-70.9%
DCTH's operating margin has surged by 98% year-on-year and by 72% since the previous quarter
Delcath Systems's net margin has surged by 97% YoY and by 53% QoQ
Delcath Systems's gross profit has soared by 68% from the previous quarter
The operating income has surged by 67% year-on-year and by 54% since the previous quarter
Growth
What is Delcath Systems's growth rate over time
Valuation
What is Delcath Systems stock price valuation
P/E
N/A
P/B
5.65
P/S
9.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.06
Delcath Systems's EPS has soared by 68% YoY and by 23% from the previous quarter
DCTH's P/B is 78% lower than its last 4 quarters average of 24.6
The company's revenue has surged by 64% QoQ
The price to sales (P/S) is 61% less than the 5-year quarterly average of 23.6 and 45% less than the last 4 quarters average of 16.6
Efficiency
How efficient is Delcath Systems business performance
Delcath Systems's ROS has soared by 97% YoY and by 52% from the previous quarter
The ROE has soared by 84% year-on-year and by 65% since the previous quarter
The company's return on invested capital has surged by 77% YoY and by 42% QoQ
The ROA has soared by 57% YoY and by 39% QoQ
Dividends
What is DCTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DCTH.
Financial health
How did Delcath Systems financials performed over time
The total assets has soared by 142% since the previous quarter and by 98% year-on-year
DCTH's total liabilities has dropped by 66% since the previous quarter and by 66% year-on-year
Delcath Systems's debt is 98% lower than its equity
DCTH's debt to equity has shrunk by 97% YoY and by 94% QoQ
Delcath Systems's debt has shrunk by 90% YoY and by 66% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.